Status:
UNKNOWN
Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Dactinomycin Adverse Reaction
Bone and Joint Infection
Eligibility:
All Genders
15+ years
Brief Summary
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria. Since the authorization of daptomycin in 2006, ...
Detailed Description
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria. The Infectious Diseases Society of America reco...
Eligibility Criteria
Inclusion
- patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (BJI/PJI)
Exclusion
- \-
Key Trial Info
Start Date :
February 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04414137
Start Date
February 19 2019
End Date
September 1 2021
Last Update
November 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Lyon, France, 69004